Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
- PMID: 35128571
- DOI: 10.1007/s00277-022-04770-6
Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
Abstract
The frequency of thrombosis in AML has been evaluated only in a few studies and no validated predictive model is currently available. Recently, DIC score was shown to identify patients at higher thrombotic risk. We aimed to evaluate the frequency of thromboembolism in AML patients treated with intensive chemotherapy and to assess the ability of genetic and clinical factors to predict the thrombotic risk. We performed a retrospective observational study including 222 newly diagnosed adult AML (210) and high-risk MDS (12), treated with intensive chemotherapy between January 2013 and February 2020. With a median follow-up of 44 months, we observed 50 thrombotic events (90% were venous, VTE). The prevalence of thrombosis was 22.1% and the 6-months cumulative incidence of thrombosis was 10%. The median time to thrombosis was 84 days and 52% of the events occurred within 100 days from AML diagnosis. Khorana and DIC score failed to stratify patients according to their thrombotic risk. Only history of a thrombotic event (p = 0.043), particularly VTE (p = 0.0053), platelet count above 100 × 109/L at diagnosis (p = 0.036) and active smoking (p = 0.025) significantly and independently increased the risk of thrombosis, the latter particularly of arterial events. AML genetic profile did not affect thrombosis occurrence. Results were confirmed considering only thromboses occurring within day 100 from diagnosis. DIC score at diagnosis, but not thrombosis, was independently associated with reduced survival (p = 0.004). Previous VTE, platelet count above 100 × 109/L and active smoking were the only factors associate with increased thrombotic risk in AML patients treated intensively, but further studies are needed to validate these results.
Keywords: Acute myeloid leukemia; Disseminated intravascular coagulation; Intensive chemotherapy; Khorana score; Thrombosis.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
OC-10 - Disseminated intravascular coagulation at diagnosis strongly predicts both arterial and venous thrombosis in acute myeloid leukemia patients.Thromb Res. 2016 Apr;140 Suppl 1:S172. doi: 10.1016/S0049-3848(16)30127-X. Epub 2016 Apr 8. Thromb Res. 2016. PMID: 27161682
-
Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia.Blood. 2016 Oct 6;128(14):1854-1861. doi: 10.1182/blood-2016-02-701094. Epub 2016 Jun 28. Blood. 2016. PMID: 27354723
-
A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis.Eur J Intern Med. 2022 Jul;101:68-75. doi: 10.1016/j.ejim.2022.04.025. Epub 2022 May 5. Eur J Intern Med. 2022. PMID: 35527180
-
Thrombosis in Myeloid Malignancies: From CHIP to AML.Cardiovasc Hematol Disord Drug Targets. 2024;24(1):2-12. doi: 10.2174/011871529X307253240530060107. Cardiovasc Hematol Disord Drug Targets. 2024. PMID: 38879768 Review.
-
Ischemic stroke as the initial presentation in acute myeloid leukemia vs. myelodysplastic syndrome: a case report and literature review with pathophysiological and clinical exploration.Neurol Sci. 2024 Jul;45(7):3297-3304. doi: 10.1007/s10072-024-07367-1. Epub 2024 Feb 14. Neurol Sci. 2024. PMID: 38351359 Review.
Cited by
-
Thrombosis in Acute Myeloid Leukemia: Pathogenesis, Risk Factors and Therapeutic Challenges.Curr Treat Options Oncol. 2023 Jun;24(6):693-710. doi: 10.1007/s11864-023-01089-w. Epub 2023 Apr 26. Curr Treat Options Oncol. 2023. PMID: 37099265 Review.
-
Risk Factors for Venous Thromboembolism in Acute Promyelocytic Leukemia.Cancers (Basel). 2024 Dec 17;16(24):4209. doi: 10.3390/cancers16244209. Cancers (Basel). 2024. PMID: 39766107 Free PMC article.
-
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience.Cancers (Basel). 2022 Nov 17;14(22):5640. doi: 10.3390/cancers14225640. Cancers (Basel). 2022. PMID: 36428732 Free PMC article.
-
Venous thromboembolism in patients with acute myeloid leukemia: development of a predictive model.Thromb J. 2024 Apr 17;22(1):37. doi: 10.1186/s12959-024-00607-6. Thromb J. 2024. PMID: 38632595 Free PMC article.
-
Editorial to the Special Issue "Recent Advances in Biochemical Mechanisms of Acute Myeloid Leukemia".Biomedicines. 2023 May 2;11(5):1339. doi: 10.3390/biomedicines11051339. Biomedicines. 2023. PMID: 37239010 Free PMC article.
References
-
- Khorana AA (2010) Venous Thromboembolism and Prognosis in Cancer. Thromb Res 125:490–493. https://doi.org/10.1016/j.thromres.2009.12.023 - DOI - PubMed - PMC
-
- Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Thromboembolism Is a Leading Cause of Death in Cancer Patients Receiving Outpatient Chemotherapy. J Thromb Haemost 5:632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x - DOI - PubMed
-
- Falanga A, Russo L, Verzeroli C (2013) Mechanisms of Thrombosis in Cancer. Thromb Res 131(Suppl 1):S59-62. https://doi.org/10.1016/S0049-3848(13)70024-0 - DOI - PubMed
-
- Blom JW, Doggen CJM, Osanto S, Rosendaal FR (2005) Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis. JAMA 293:715–722. https://doi.org/10.1001/jama.293.6.715 - DOI - PubMed
-
- Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of Cancer-Associated Venous Thrombosis. Blood 122:1712–1723. https://doi.org/10.1182/blood-2013-04-460121 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous